摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-O-cyanophenyl-amine | 1309593-61-0

中文名称
——
中文别名
——
英文名称
(6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-O-cyanophenyl-amine
英文别名
(6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-o-cyanophenylamine;2-[(6-Bromo[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino]benzonitrile;2-[(6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino]benzonitrile
(6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-O-cyanophenyl-amine化学式
CAS
1309593-61-0
化学式
C13H8BrN5
mdl
——
分子量
314.144
InChiKey
LAOJWVQZPCXPAP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    66
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Triazolopyridine derivates
    申请人:Bayer Schering Pharma AG
    公开号:EP2343295A1
    公开(公告)日:2011-07-13
    The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of proliferative diseases, as well as to intermediate compounds useful in the preparation of said compounds.
    本发明涉及一般式(I)的三唑吡啶类化合物,这些化合物是单极纺锤体1激酶(Mps-1或TTK)抑制剂:其中R1、R2、R3、R4和R5如描述和索赔中所述,涉及制备该类化合物的方法,含有该类化合物的药物组合物和配方,以及利用该类化合物制造用于治疗或预防增殖性疾病的药物组合物的用途,以及用于制备该类化合物的中间化合物。
  • Triazolopyridines
    申请人:Bayer Schering Pharma AG
    公开号:EP2343297A1
    公开(公告)日:2011-07-13
    The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of proliferative diseases, as well as to intermediate compounds useful in the preparation of said compounds.
    本发明涉及一般式(I)的三唑吡啶化合物,其为单极纺锤体1激酶(Mps-1或TTK)抑制剂:其中R1、R2、R3、R4和R5如描述和索赔中所示,以及制备所述化合物的方法,包括所述化合物的药物组合物和组合物,用于制造用于治疗或预防增殖性疾病的药物组合物的用途,以及用于制备所述化合物的中间化合物。
  • [EN] TRIAZOLOPYRIDINES<br/>[FR] TRIAZOLOPYRIDINES
    申请人:BAYER SCHERING PHARMA AG
    公开号:WO2011063908A1
    公开(公告)日:2011-06-03
    The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis proliferative of diseases, as well as to intermediate compounds useful in the preparation of said compounds.
    本发明涉及通式(I)的三唑吡啶化合物,这些化合物是单极纺锤体1激酶(Mps-1或TTK)抑制剂: 公式(I),其中R1、R2、R3、R4和R5如描述和索赔中所示,以及制备所述化合物的方法,包括包含所述化合物的药物组合物和药物组合物,用于制造用于治疗或预防增殖性疾病的药物组合物的用途,以及用于制备所述化合物的中间化合物。
  • TRIAZOLOPYRIDINES
    申请人:Schulze Volker
    公开号:US20120328610A1
    公开(公告)日:2012-12-27
    The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R 1 , R 2 , R 3 , R 4 , and R 5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis proliferative of diseases, as well as to intermediate compounds useful in the preparation of said compounds.
    本发明涉及一种三唑吡啶化合物,通式为(I),其为单极纺锤体1激酶(Mps-1或TTK)抑制剂:公式(I),其中R1、R2、R3、R4和R5如说明书和权利要求中所述,以及制备该化合物的方法,包括该化合物的制药组合物和配方,使用该化合物制造用于治疗或预防增生性疾病的制药组合物,以及在制备该化合物中有用的中间体化合物。
  • TRIAZOLOPYRIDINE DERIVATIVES
    申请人:Koppitz Marcus
    公开号:US20130121994A1
    公开(公告)日:2013-05-16
    The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors in which R 1 , R 2 , R 3 , R 4 , and R 5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of proliferative diseases, as well as to intermediate compounds useful in the preparation of said compounds.
    本发明涉及一般式(I)的三唑吡啶化合物,其为单极纺锤体1激酶(Mps-1或TTK)抑制剂,其中R1、R2、R3、R4和R5如说明书和权利要求中所述,以及制备该化合物的方法,包括该化合物的药物组成物和组合物,以及用于制造治疗或预防增生性疾病的药物组成物的该化合物的用途,以及制备该化合物的中间体化合物。
查看更多

同类化合物

苯甲醇,2-甲基-a-[1-(甲基氨基)环戊基]- 溴-6-甲基[1,2,4]噻唑并[1,5-a]吡啶 乙基[1,2,4]三唑并[1,5-a]吡啶-2-羧酸酯 三(二甲基氨基)(3H-1,2,3-三唑[4,5-b]吡啶-3-基氧代)膦六氟磷酸盐 [1,2,4]噻唑并[4,3-a]吡啶-3-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-8-胺 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-6-甲腈 [1,2,4]噻唑并[1,5-a]吡啶-6-甲胺 [1,2,4]噻唑并[1,5-a]吡啶-5-羧醛 [1,2,4]噻唑并[1,5-a]吡啶-5-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-2-羧醛 [1,2,4]三氮唑[1,5-A]吡啶-6-甲醛 [1,2,4]三唑并[4,5-a]吡啶-3-磺酰胺 [1,2,4]三唑并[4,3-a]吡啶-5-羧酸 [1,2,4]三唑并[4,3-a]吡啶-5-硫醇 [1,2,4]三唑并[4,3-A]吡啶-8-胺 [1,2,4]三唑并[4,3-A]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-6-胺 [1,2,4]三唑并[1,5-a]吡啶-5-羧酸 [1,2,4]三唑并[1,5-a]吡啶 [1,2,4]三唑并[1,5-A]吡啶-7-羧酸甲酯 [1,2,4]三唑并[1,5-A]吡啶-7-硼酸 [1,2,4]三唑[4,3-A]嘧啶-6-羧酸 [1,2,4]三唑[4,3-A]吡啶-3-硫醇 [1,2,4]三唑[1,5-a]吡啶-2-甲酸 [1,2,3]三唑并[1,5-a]吡啶-7-甲醛 [1,2,3]三唑并[1,5-a]吡啶-7-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰氯 N-羟基-7-氮杂苯并三氮唑 N-[5-[(1-甲基乙基)氨基]-7-(三氟甲基)[1,2,4]三唑并[1,5-a]吡啶-2-基]-3-吡啶甲酰胺 N,N-二乙基-7-硝基-1H-1,2,3-三唑并[4,5-c]吡啶-1-乙胺 GLPG-0634 中间体 ALK4/ALK5抑制剂 9-环戊基-7-乙基-3-(2-噻吩基)-6,9-二氢-5H-吡唑并[3,4-c][1,2,4]三唑并[4,3-A]吡啶 8-硝基[1,2,4]三唑并[4,3-a]吡啶 8-硝基[1,2,4]三唑并[1,5-a]吡啶 8-甲氧基-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲氧基-5-碘-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲基-[1,2,4]三唑并[1,5-A]吡啶 8-甲基-1,2,4噻唑并1,5-a吡啶-2-胺 8-溴2-甲基-[1,2,4]噻唑并[1,5-a]吡啶 8-溴-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-溴-[1,2,4]三氮唑并[4,3-A]吡啶 8-溴-[1,2,4]三唑并[1,5-A]吡啶 8-溴-[1,2,4]三唑[4,3-a]吡啶-6-羧酸 8-溴-6-氯-2-甲基-[1,2,4]噻唑并[1,5-a]吡啶